![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ANTISOMA TO TEST AS1409 IN RENAL CANCER, MELANOMA PATIENTS
ANTISOMA TO TEST AS1409 IN RENAL CANCER, MELANOMA PATIENTS
Antisoma has announced it will begin a Phase I trial of AS1409 in patients with renal cancer and melanoma. High levels of the drug's target are found in these cancers.
AS1409 is a fusion protein with two components. One is the cytokine IL12, which is known to have anti-cancer effects. The other is an antibody that binds to EDB fibronectin, a protein associated with tumor blood vessels in a wide range of cancers. AS1409 is designed to be a targeted therapy that delivers IL12 specifically to tumors.
Studies in mice with prostate, colorectal and skin cancers have shown that the drug blocks cancer growth more effectively than an equivalent dose of untargeted IL12. AS1409 is also expected to cause fewer side effects than IL12.
Past clinical trials have suggested that melanoma and renal cancer are particularly sensitive to IL12. These cancers were therefore tested for EDB fibronectin to assess the potential for targeting by AS1409.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct